Targeting the Renin-Angiotensin System in Patients with Renal Disease

Parving H.H. , Andersen A.R. , Smidt U.M. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; i: 1175–9

Hovind P. , Rossing P. , Tarnow L. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 2001; 60: 277–83

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13

Petersen J.C. , Adler S. , Burkart J.M. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754–62

Remuzzi G. , Ruggenenti P. , Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2–15

Rossing P. , Hommel E. , Smidt U.M. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511–16

De Jong P.E. , Navis G.J. , De Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999; 354: 352–3

Lewington A.J. , Arici M. , Harris K.P. Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits? Nephrol Dial Transplant 2001; 16: 885–8

Lewis E.J. , Hunsicker L.G. , Bain R.P. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62

Kasiske B.L. , Kalil R.S. , Ma J.Z. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129–38

Bohlen L. , de Courten M. , Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S–92S

Parving H.H. , Hommel E. , Jensen B.R. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60: 228–34

Crepaldi G. , Carta Q. , Deferrari G. Effects of lisinopril and nifedipine on the progression of overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21: 104–10

Mathieson E.R. , Hommel E. , Hansen H.P. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999; 319: 24–5

Viberti G.C. , Mogensen C.E. , Groop L.C. Effect of captopril on progression to clinical proteinuria with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275–9

The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with diabetes and normo-albuminuria or microalbuminuria. Lancet 1997; 349: 1787–92

The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370–9

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–8

Zatz R. , Dunn B.R. , Meyer T.W. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925–30

Andersen S. , Tarnow L. , Rossing P. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601–6

Buter H. , Navis G. , Dullaart R.P. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001; 16: 771–5

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9

Ravid M. , Lang R. , Rachmani R. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7 year follow-up study. Arch Intern Med 1996; 156: 286–9

Ravid M. , Savin H. , Jutrin I. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–81

Ruggenenti P. , Remuzzi G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant 2000; 15: 1900–2

Parving H.H. , Lehnert H. , Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8

Lewis E.J. , Hunsicker L.G. , Clarke W.R. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60

Brenner B.M. , Cooper M.E. , de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9

Dahlöf B. , Devereux R.B. , Kjeldsen S.E. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003

Lindholm L.H. , Ibsen H. , Dahlöf B. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10

Mann J.F. , Gerstein H.C. , Pogue J. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–36

Valabhji J. , Robinson S. , Poulter C. Prevalence of renal artery stenosis in subjects with type 2 diabetes and coexistent hypertension. Diabetes Care 2000; 23: 539–43

Jafar T.H. , Schmid C.H. , Landa M. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Intern Med 2001; 135: 73–87

Jafar T.H. , Stark P.C. , Schmid C.H. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131–40

Ruggenenti P. , Perna A. , Remuzzi G. ACE Inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post-hoc analysis of the REIN trial results. J Am Soc Nephrol 2001; 12: 2832–7

Plum J. , Bunten B. , Nemeth R. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9: 2223–34

Bakris G.L. , Siomos M. , Richardson D. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000; 58: 2084–92

Reilly C.F. , Tewksbury D.A. , Schechter N.M. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 1982; 257: 8619–22

Komers R , and Cooper M.E. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Am J Physiol 1995; 268(4 pt2): F588–94

Russo D. , Pisani A. , Balletta M.M. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kid Dis 1999; 33: 851–6

Ruilope L.M. , Aldigier J.C. , Ponticelli C. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens 2000; 18: 89–95

Mogensen C.E. , Neldam S. , Tikkanen I. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–4

Chrysostomov A. , Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925–6

British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320: 705–8